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DISTRIBUTION OF CIRCULATING AND GLOMERULAR IGG SUBCLASSES 
AGAINST FULL-LENGTH ANTI- PHOSPHOLIPASE A2 RECEPTOR AND ITS 
EPITOPES IN PRIMARY MEMBRANOUS NEPHROPATHY 
 
LEE CHUAN LI 
ABSTRACT 
 
Objective: Research towards understanding PLA2R, the human antigen of primary 
membranous nephropathy has steadily gained ground since its discovery in 2009. This 
autoimmune kidney disease features a unique immunological character of high IgG4 
prevalence, both in circulation and as immune complexes deposited in tissue. We seek to 
characterize and better understand the distribution of all IgG subclasses between serum 
and glomerular deposits, as well as characterize IgG reactivity directed against both full-
length PLA2R and its immunogenic components. 
 
Methods: Using biopsy data obtained from renal pathology centers, we identified 13 
patients with primary membranous nephropathy as well as biopsy immunofluorescence 
data for all IgG subclasses. We compared anti-PLA2R staining in glomeruli to serum anti-
PLA2R using western blot, and analyzed concordance of subclass distribution between 
the two sets of data using Cohen’s kappa score. We also studied and similarly analyzed, 
using western blot, subclass distribution of IgG against PLA2R epitopes CysR, CTLD1, 
and CTLD4-8. 
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Results: All 13/13 (100%) patient samples were positive for circulating anti-PLA2R 
IgG4 in western blot, with 11/13 (84.6%) positive for IgG3, 6/13 (46.2%) for IgG2, and 
11/13 (84.6%) for IgG1. When compared with biopsy immunofluorescence these results 
exhibited fair agreement for IgG4, IgG3, and IgG1; IgG2 was discordant with 
corresponding biopsies. For reactivity against PLA2R epitopes, 11/12 (91.7%) samples 
were positive for anti-CysR IgG4, 5/12 (41.7%) positive for IgG3, 0/11 (0.0%) for IgG2, 
and 8/11 (72.7%) for IgG1. Reactivity against epitopes CTLD1 and CTLD4-8 was 
detected less frequently than against CysR, though IgG4 was still the predominant 
subclass in almost all cases. 
 
Conclusion: In general, levels of circulating IgG subclasses directed against PLA2R is 
concordant between serum and in biopsy, and as such serum anti-PLA2R can act as a 
good proxy for all IgG subclasses found in glomerular deposits. Furthermore, both full-
length PLA2R and its extracellular domain containing the CysR epitope exhibit 
concordance between IgG3 and IgG4 levels, demonstrating potential for anti-CysR 
autoantibodies to be a good indicator for primary MN in addition to anti-PLA2R. 
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INTRODUCTION 
 
Overview 
Membranous nephropathy (MN) is an autoimmune kidney disease affecting the 
glomerulus, characterized by in situ subepithelial immune complex formations depositing 
within the glomerular basement membrane (GBM) of podocytes, and subsequently 
causing damage to glomerular filtration barrier (Salant & Cattran, 2010). It is the most 
common cause of nephrotic syndrome in adults aged 60 or older, and though more rare in 
children (Jaipaul, 2013), often leads to severe proteinuria and edema in patients. About 
one-third to half of all patients experience eventual progression to end-stage renal disease 
and kidney failure within several years, though spontaneous clinical remission as well as 
abated disease progression may also occur (UNC Kidney Center, n.d.). The first-year 
mortality rate for end-stage renal disease from all causes is approximately 200 per 1000 
patients, and as such MN represents a notable healthcare concern in the United States 
(United States Renal Data System, 2014). Clinically about three-quarters of cases 
(Cattran & Rennke, 2014) are classified as primary MN—previously called idiopathic 
MN—and have no clear etiology. In contrast, the remaining quarter of cases develop 
secondary to a pre-existing medical condition or infection, exposure to chemicals and 
toxins, or as a side-effect of certain drug treatment regimens (Table 1) (Salant & Cattran, 
2010). 
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Table 1, Causes of secondary membranous nephropathy. A non-comprehensive list of 
diseases and conditions associated with and causative of secondary MN (Salant & Cattran, 2010, 
p. 240). 
Category Condition 
Immune disorders Systemic lupus erythematosus 
 Graft-versus-host disease 
 Lupus nephritis 
Infections Hepatitis B 
 Hepatitis C (less common) 
 HIV 
Drugs/toxins Penicillamine 
 Mercury-containing compounds 
 NSAIDs, COX-2 inhibitors 
Other Malignancies and tumors 
 Sarcoidosis 
 Kidney transplantation (de novo MN) 
  
 
A brief history and background of MN 
MN was initially defined as nephrotic glomerulonephritis, a condition 
characterized by edema and severe proteinuria with a more “distinguished pathology” as 
the disease progressed (Jones, 1957). Subsequently, an inducible model of rat MN was 
developed and studied extensively as an animal model for the disease in humans, long 
before identification of an endogenous human antigen (Heymann, et al., 1965). 
Eponymously named Heymann nephritis, experiments involving this model led to the 
discovery of the 330-kDa glycoprotein gp330 (eventually to be identified as a component 
of megalin), a rat podocyte and tubule brush-border protein antigen responsible for the 
formation of granular immune complex deposits in the glomerulus and development of 
proteinuria (Kerjaschki & Farquhar, 1982). Thereafter a 400-kDa protein (LRP2) similar 
to megalin was also found in proximal tubules of human kidneys, though LRP2 is 
localized to neither the glomerulus nor detectable in immune complexes, and thus 
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insufficient to explain development of MN in humans (Kerjaschki, et al., 1987). In the 
Heymann nephritis animal model, podocyte damage and subsequent proteinuria is caused 
by IgG-mediated complement cascade activation (Kerjaschki & Neale, 1996). Despite the 
knowledge Heymann nephritis provided towards understanding animal models of MN, a 
firm connection to the human disease had yet to be made at this point because the human 
antigenic target still remained elusive. Nevertheless, progress occurred with the 
identification of the approximately 90-kDa protein neutral endopeptidase (NEP, also 
neprilysin), a human podocyte antigen that is also expressed in various other tissues, 
including the fetal placenta. NEP is responsible for a form of fetal MN that develops 
prenatally (Debiec, et al., 2002). The resultant alloimmune MN is characterized by 
circulating maternal anti-NEP antibodies which, due to maternal deficiency of a gene 
coding for NEP and previous sensitization from miscarriage, cross the placenta and 
specifically target fetal podocytes (Debiec & Ronco, 2007). This discovery represents the 
first endogenous podocyte antigen directly responsible for MN in humans. And though 
NEP is not responsible for the primary disease, similarities between alloimmune MN and 
Heymann nephritis offered more support that a glomerular antigen was also responsible 
for development of primary MN in humans. 
A human antigen specific for primary MN was eventually discovered in 2009, 
which identified the 185-kDa M-type phospholipase A2 receptor (PLA2R): PLA2R 
(Figure 1) is a member of the mannose receptor family and a type-1 transmembrane 
glycoprotein whose immunogenicity is sensitive to reducing conditions but not N-
glycosylation (Beck, et al., 2009). In this study, serum from approximately 70% of 
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patients with primary MN—and none in healthy controls or those with secondary MN—
were found to specifically bind both native and recombinant human PLA2R. Like 
megalin and NEP, PLA2R is expressed on the basal surface of podocytes, though its 
expression is greatly increased in humans compared to other species. Circulating anti-
PLA2R IgG binds to podocytes, becomes capped, and is shed and deposited in the 
podocyte GBM to form immune complexes, whereupon clinical symptoms such as 
proteinuria and edema can result by as-of-yet unclear pathological mechanisms (Hofstra 
& Wetzels, 2012). 
 
Figure 1, Extracellular domains of PLA2R. The N-terminus contains a cysteine-rich ricin 
(CysR) domain, followed by a collagenous fibronectin-like type II domain (FNII), C-type lectin 
domains (CTLD) 1-8, and finally a transmembrane and intracellular region towards the C-
terminus. The receptor is believed to be capable of folding its extracellular regions via disulfide 
bonding: its conformation-dependent epitopes are sensitive to reducing conditions, in which 
reactivity to anti-PLA2R autoantibodies is largely abolished (Beck, 2015). Factors leading to 
PLA2R acting as an autoantigen have yet to be completely determined. 
 
Prior to the discovery of PLA2R, analyzing renal biopsies using light and electron 
microscopy was the primary method to obtain a definitive MN diagnosis. The 
histological characteristics and ultrastructure of glomeruli, along with associated clinical 
features, were first outlined by Jones in 1957. Prominent features visible in light 
microscopy include glomerular capillary wall and GBM thickening, with subepithelial 
“spikes” that extend from the GBM around immune complex deposits (Figure 2B & 2C); 
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the granular deposits and thickened GBM can be visualized in more detail by electron 
microscopy (Figure 3) (Elsanjak & Prabhakar, 2011). Ultrastructural staging of MN by 
electron microscopy uses the aforementioned subepithelial spikes to characterize the 
extent of GBM expansion, with earlier stages associated with more favorable clinical 
outcomes (Ehrenreich & Chung, 1968). 
 
Figure 2, Histology in normal and membranous glomeruli. (A) Ultrastructure of normal 
glomerulus visualized using electron microscopy, showcasing elements of the filtration barrier. 
(B) Glomerulus with MN, showing GBM thickening (arrows) and mesangial hyperplasia 
(asterisks). (C) Immunofluorescence of glomerulus with MN, showing granular IgG deposition 
along capillary walls. Adapted from (Boston University School of Medicine, n.d.) and (Cattran & 
Rennke, 2014). 
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Figure 3, Subepithelial spikes on membranous glomerulus. Close-up light microscopy of 
glomerulus with membranous nephropathy, showcasing characteristic GBM “spikes” (arrows) 
extending around immune complex deposits. Adapted from (Elsanjak & Prabhakar, 2011). 
 
Mechanisms and pathology: IgG and the complement cascade 
The proposed mechanism of damage and disease progression requires an 
overview of immunoglobulins, of which there are five isotypes in humans, and its role in 
complement activation. First described by von Behring and Kitasato in the late 19th 
century, subsequent research demonstrated that serum antibodies were able to offer 
protection against disease by neutralizing toxins as well as lysing bacteria (Kuby, 1997). 
There are five antibody isotypes which differ in the composition of their heavy chains, 
providing the molecule with its unique properties. Of these, IgG constitutes the majority 
isotype in human serum, and is largely responsible for humoral immunity via 
opsonization, neutralization, and complement activation (Kuby, 1997), as well as almost 
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exclusively representing the isotype found in immune complex deposits of primary MN 
(Salant & Cattran, 2010). IgG is composed of four subclasses each with a range of 
individual properties: susceptibility to proteolytic cleavage, hinge flexibility, efficacy in 
binding chemically distinct targets are among these (Table 2). More specifically, in 
primary MN the autoantibodies against PLA2R are predominantly of the IgG4 variety 
with lesser contribution from the other subclasses as seen in immune complex deposits 
(Doi, Mayumi, Kanatsu, Suehiro, & Hamashima, 1984), and also in serum as measured 
by ELISA and IFA (indirect immunofluorescence assay) (Hofstra, et al., 2012). This is in 
contrast with the expected distribution of circulating IgG subclasses within healthy adults 
(Hamilton, 2001), though during earlier stages of primary MN progression the immune 
deposits contain more IgG1 and IgG3 (Huang, et al., 2013). Owing to these observations, 
predominance of IgG4 in glomerular deposits frequently becomes a distinguishing feature 
and diagnostic marker of primary MN, and its majority presence is often contrasted to 
secondary MN. For example, in cases of membranous lupus nephritis biopsy 
immunofluorescence indicated a more equal distribution of IgG subclasses in glomerular 
deposits, with IgG1 and IgG2 more frequently detected in both serum and biopsy instead 
of IgG4 (Kuroki, et al., 2002). In addition, patients with malignancy-associated secondary 
MN also exhibited heightened IgG1 and IgG2 deposition in glomeruli, demonstrating a 
distinguishing feature between primary from secondary forms of MN (Ohtani, et al., 
2003). 
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Table 2, Chemical and biological properties of IgG. Key properties of the four IgG subclasses 
in healthy adults. Of note, circulating IgG4 represents the least common subclass by amount and 
percentage in humans, and is incapable of activating complement via the classical pathway. Data 
obtained from (Meulenbroek & Zeijlemaker , n.d.) and (Hamilton, 2001, pp. 28-29). 
Property Subclass 
 IgG1 IgG2 IgG3 IgG4 
Serum amt. g/L (%) 8 (60-70) 4 (14-20) 0.8 (4-8) 0.4 (2-6) 
Molecular mass (kDa) 146 146 170 146 
Hinge region     
    # of residues 15 12 62 12 
    # of disulfide bonds 2 4 11 2 
Immunogenicity     
    vs. proteins Moderate Weak Moderate Weak 
    vs. polysaccharides Weak Moderate None None 
    vs. allergens Weak None None Moderate 
Complement activation     
    C1, classical Moderate Weak Strong None 
    C3, alternative None Weak None Weak 
     
 
 
Figure 4, Formation of subepithelial immune complexes. Methods for immune complex 
accumulation in the GBM: (A) circulating antibodies which bind an endogenous antigen (e.g., 
PLA2R, NEP) on podocyte basal surfaces are eventually shed onto the GBM, forming deposits in 
situ and resulting in damage to the podocyte filtration barrier; (B) positively-charged proteins 
(e.g., cBSA) are attracted to the negatively-charged GBM, becoming an exogenous antigen; (C) 
pre-formed circulating immune complexes may cross into and deposit on the GBM. Adapted 
from (Beck & Salant, 2014). 
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There are several mechanisms that can cause immune complexes to form on the 
podocyte GBM (Figure 4). In addition to an in situ autoimmune process (such as in the 
cases of NEP and PLA2R), both preformed circulating immune complexes and cationic 
bovine serum albumin (cBSA) can lead to buildup of glomerular deposits, though these 
do not contribute to the pathogenesis of primary MN (Beck & Salant, 2014). In animal 
models and rare cases of childhood MN (Debiec, et al., 2011), cBSA was able to cross 
the filtration barrier and become embedded in the anionic GBM, thus becoming a target 
for circulating anti-BSA antibodies (Border, Ward, Kamil, & Cohen, 1982). In secondary 
MN, causative diseases such as systemic lupus erythematosus initially involves immune 
complex formation in circulation before depositing in the GBM (Mok & Lau, 2003). 
Once immune complexes have accumulated, it was believed that in models of passive 
Heymann nephritis the IgG contained in these deposits caused podocyte injury and 
proteinuria through activation of the complement cascade, evidenced by concurrent 
presence of complement component C3 (Salant, Belok, Madaio, & Couser, 1980). To 
introduce complement system briefly (Figure 5), a series of serum proteins beginning 
with component C1 in the classical pathway—and cleavage product C3b in the 
alternative pathway—is enzymatically cleaved, each reaction product catalyzing the next, 
eventually activating C3 convertase and forming the membrane attack complex (MAC) 
composed of complement proteins C5b-C9 (Kuby, 1997). The MAC inserts into the 
target cell’s lipid bilayer and forms transmembrane channels, promotes a local cytotoxic 
environment rich in oxidative species and inflammatory agents (Kerjaschki & Neale, 
1996), and leads to “disruption of the actin cytoskeleton [and] causes altered cell-matrix 
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adhesion and loss or displacement of slit diaphragms…and loss of the filtration barrier to 
protein” (Salant & Cattran, 2010). Further research suggested that complement activation 
in human MN underwent a parallel mechanism, in which for most cases presence of C3 
and its breakdown products can be detected (Segawa, et al., 2010). 
 
 
Figure 5, Roles and activation of the complement system. Three pathways leading to 
activation of the complement cascade. The classical pathway is involved in secondary MN, and 
initiated by C1 interaction with antibody-antigen complexes. All three pathways leads to C3 
convertase and the formation of C5b-9 (MAC), a molecule which promotes a cytotoxic 
environment by way of reactive oxygen species and inflammatory agents. Cleavage products C3a, 
C5a, and C3b have additional roles in the innate immune system. Taken from (Janeway, Travers, 
Walport, & Shlomchik, 2004). 
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While pathogenesis due to complement activation (as in rat the Heymann 
nephritis model) is a tempting culprit, there are still unanswered questions regarding the 
disease mechanism in humans: the glomerular immune complex deposits of primary MN 
contains predominantly IgG4, which is incapable of fixing complement components via 
the classical pathway as previously described (Meulenbroek & Zeijlemaker , n.d.). This is 
in contrast to the increased amounts of other IgG subclasses found in glomerular deposits 
of patients with secondary MN, which provides evidence for a clearer pathological 
mechanism. Nevertheless, it has been proposed that the relatively larger IgG1 and IgG3 
deposition initially present in early phases of primary MN may be sufficient to induce 
complement-mediated podocyte injury (Huang, et al., 2013). Occasional but sparse 
detection of C3 in biopsies of individuals specifically with primary MN lends some 
credence to involvement of the classical pathway, though currently there is not enough 
conclusive data to confirm this hypothesis (Ma, Sandor, & Beck, 2013). 
 
Applications of research and clinical connections 
The literature in this field has been rapidly growing, and reveals new questions in 
addition to answering old ones. Firstly, as IgG4 is unable to fix complement its 
predominance in primary MN calls into question its pathogenicity, and attempts to test 
this by overexpressing PLA2R in animal models have been unsuccessful (Ronco & 
Debiec, 2014), though there is some circumstantial evidence implicating its involvement 
in complement cascade activation via the mannose-binding lectin pathway (Ma, Sandor, 
& Beck, 2013). Secondly, in the pivotal study circulating IgG against PLA2R was 
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successfully detected in 70% of patients with biopsy-proven primary MN (Beck, et al., 
2009), though this percentage varied considerably from approximately half positive up to 
86% (Hofstra & Wetzels, 2012). Serum anti-PLA2R autoantibodies have been shown to 
exhibit very high specificity, in contrast to their comparatively lower sensitivity—this 
observation may be attributed to several factors, from differing experimental methods to 
immunological reasons concerning each patient. For example, a cohort of Japanese 
nephrotic patients exhibited lower overall anti-PLA2R titers compared to other Asian and 
European cohorts (Akiyama, et al., 2014), suggesting that immunological aspects MN 
may manifest differently among distinct ethnic groups. Additionally, MN has been shown 
to undergo immunological remission and relapse (Figure 6) in which lowered serum anti-
PLA2R levels are associated with higher likelihood of spontaneous clinical remission 
(Hofstra, et al., 2012). The clinical disease can persist for several months after 
immunological remission occurs (Beck & Salant, 2014), making it difficult to pinpoint an 
exact place along the disease continuum. This time lapse and the uncertainty in 
measurement it brings can contribute to observed interstudy variations in sensitivity. 
Therefore, it is possible that due to methodological and population differences among the 
various studies, including elapsed time between dates of patient biopsy, their 
corresponding date of data collection, and time-delayed effects of therapeutic regimens, 
heterogeneous results may be produced when assessing diagnostic sensitivity of anti-
PLA2R (Du, et al., 2014). 
13 
 
Figure 6, Time course of serum anti-PLA2R and clinical symptoms. Hypothetical case of 
primary MN conceptually illustrating the level of serum anti-PLA2R (immunological disease) and 
level of proteinuria (clinical disease). As with all typical cases, there is a delay between the onset 
of immunological remission and clinical remission, which can be on the order of several months 
to upwards of a year. 
 
With some rare exceptions, anti-PLA2R autoantibodies are a risk factor for 
developing nephrotic proteinuria, a common symptom of primary MN (Hoxha, Harendza, 
Pinnschmidt, Panzer, & Stahl, 2014). The exact pathogenic nature of anti-PLA2R is still 
unknown, though this does not necessarily diminish the clinical value of measuring these 
autoantibodies: studies have shown that serum anti-PLA2R levels correlate with urinary 
protein excretion, are typically absent during clinical remission, and predict clinical 
relapse and long-term outcome of primary MN patients (Hofstra, Beck, Beck, Wetzels, & 
Salant, 2011). Their relationship is more definitively demonstrated with depletion of 
circulating anti-PLA2R autoantibodies induced by rituximab—a drug used for 
immunosuppression therapy in primary MN—whereby clinical remission is more likely 
after anti-PLA2R levels subside (Beck, et al., 2011). Using a variety of different 
conditions and methodologies measuring both serum and glomerular autoantibodies, 
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researchers were able to demonstrate the diagnostic and prognostic value of anti-PLA2R: 
patients with greatly reduced autoantibody levels were much more likely to eventually 
undergo clinical remission compared to those with persistent levels within a similar time 
frame. In our study, we also hope to examine further this link between deposited 
glomerular IgG and corresponding anti-PLA2R IgG subclasses in circulation. 
A developing topic of current primary MN research is characterizing epitope 
specificity of anti-PLA2R autoantibodies. It is widely known that PLA2R exists in both 
linear and folded configurations, and contains conformational epitopes. In addition to our 
own work, two research groups have recently published their findings identifying an 
immunodominant region of PLA2R. A research group from UCLA has created a panel of 
PLA2R constructs, beginning with the CysR-FNII epitopes and for each new construct 
adding subsequent CTLD epitopes toward the C-terminus, ultimately assembling the 
entire extracellular PLA2R domain (Kao, Lam, Waldman, Glassock, & Zhu, 2015). They 
conclude that the immunodominant epitope lies exclusively within the CysR-FNII-
CTLD1 domains, as its immunogenicity and susceptibility to reducing conditions mirror 
that of full-length PLA2R. Another research group from the United Kingdom furthered 
these findings by demonstrating immunogenicity of a distinct 31-chain polypeptide 
within the CysR domain (Fresquet, et al., 2015). While both groups also acknowledged 
occasional autoantibody reactivity to the CTLD4-8 regions, the nature of this interaction 
is more surreptitious with regards to primary MN, and its detection is generally 
inconsistent. The preliminary work done by these two groups explores the well-
established paradigm of IgG4 predominance in primary MN, and whether this also 
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extends to PLA2R epitopes or not. In this study, and in addition to reactivity against full-
length PLA2R, we hope to build upon knowledge regarding reactivity of circulating IgG 
subclasses against epitopes within PLA2R. 
 
Specific aims of research 
 Though IgG4 predominance has been well-established for primary MN by both 
serology and biopsy, our study seeks to explore in greater detail the relationship between 
all IgG subtypes, whether in circulation or deposited in glomeruli. 
In particular, we used data in biopsy reports of patients with primary MN, 
obtained from renal centers which routinely perform biopsy immunofluorescence for the 
four IgG subclasses. The biopsy data will then be compared to corresponding serum 
samples collected from these same patients, and the concordance between strength of IgG 
subclasses in serum and in biopsy will be examined. We will also analyze the extent to 
which IgG subclass reactivity against PLA2R epitopes agree with reactivity against the 
full-length molecule. Finally, we will seek to find any correlations between subclass 
responses and baseline clinical characteristics, as provided for by the biopsy reports, for 
each patient. 
Characterization of anti-PLA2R IgG responses will ideally add to the growing 
field of MN research. We hope that these results will further reinforce the relationship 
between circulating and deposited autoantibodies against full-length PLA2R and its 
epitopes for the IgG subclasses.  
16 
METHODS 
 
Samples and selection 
 In our experiments we targeted PLA2R contained in human glomerular extract 
(HGE). To prepare HGE we obtained healthy kidneys that were provided by the New 
England Organ Bank from deceased individuals. We thawed and cut frozen kidney tissue 
into a fine mince, which was then processed by sieving (Fisher Scientific Nos. 140, 80, 
200) and thorough washing with cold PBS. The remaining glomeruli we homogenized 
and proteins were extracted with SDS. Finally, we depleted any contaminating human 
IgG using Immobilized Protein G Plus (Fisher Scientific), and verified depletion of 
residual IgG using western blot (data not shown). The processed HGE aliquots were then 
prepared under non-reducing conditions for use in SDS-PAGE, and heated at 95oC for 5 
minutes. Thus, HGE proteins used in subsequent western blots were free of most 
hydrogen bonds and non-polar hydrophobic interactions while still maintaining the 
disulfide bonds necessary for reactivity with anti-PLA2R (Ophardt, 2003). 
Biopsy reports with clinical characteristics and corresponding frozen patient 
serum samples were obtained from renal pathology centers which routinely perform IgG 
immunofluorescence (Table 3). These staining procedures visualized all IgG subclasses 
deposited in glomeruli, and may include other IgG in addition to those specific for 
PLA2R. We selected those patients who were diagnosed for primary MN and seropositive 
for anti-PLA2R. We further refined our selection by only choosing those patients with 
data on immunofluorescence staining for all IgG subclasses, and our criteria yielded a 
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final selection of 13 patient samples (Figure 7). A full table of all patients and their 
associated clinical information is also available in the appendix (Table 16) 
 
Table 3, Summary data for patient samples. Patient data was obtained from biopsy reports. 
1Circulating IgG of all subclasses against human recombinant PLA2R as measured by ELISA. 
2Immunofluorsecence scores transcribed directly from biopsy reports. 4Months elapsed after 
biopsy date that serum sample was taken. Values are reported as mean ± standard deviation or n 
(%). 
Patient data, n = 13 
 Mean ± S.D. Range 
Age (years) 60.3 ± 14.2 34, 79 
Male, n 7 (53.8)  
Ethnicity, n   
    Asian 2 (15.4)  
    Caucasian 10 (76.9)  
Clinical information   
    Serum creatinine (mg/dL) 1.60 ± 0.77 0.67, 3.02 
    Serum albumin (g/dL) 2.70 ± 0.80 1.7, 4.0 
    UPCR 9.78 ± 5.43 3.13, 19.70 
    Anti-PLA2R1 (RU/mL) 150.5 ± 152.2 13.7, 493.4 
Immunohistological staining2   
    C3 2.0 ± 1.0 0, 3 
    C1q 0.5 ± 0.7 0, 2 
    Total IgG 3.7 ± 0.4 3, 4 
Months after Bx3 5.2 ± 5.7 -0.6, 19 
   
 
 
Figure 7, Selection criteria for patient samples. The full list of 543 patients, from which we 
refined our final selection of patient samples. Diagnosis of primary MN had been previously 
determined by biopsy. 
 
 
All available Bx reports 
(n = 543) 
Primary MN+ 
(n = 274) 
PLA2R+ 
(n = 124) 
IgG subclass staining 
(n = 13) 
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Western blot: full-length PLA2R and PLA2R epitopes 
We followed standard procedures for western blot with HGE, under non-reducing 
conditions with SDS-PAGE and nitrocellulose membrane for transfer electrophoresis. 
Primary antibody consisted of patient serum samples diluted to 1:100 (all serum and 
antibodies were diluted in 1x TBS/0.2% Tween-20 with 10% nonfat dry milk). For the 
secondary antibodies, we used affinity-purified sheep anti-human IgG1-4 (Table 4) at 
dilutions recommended by the manufacturer (Binding Site). For our detection antibodies 
we used donkey anti-sheep IgG conjugated with horseradish peroxidase (Sigma) diluted 
to 1:10,000 and detected by chemical luminescence. 
 
Table 4, HRP-conjugated secondary antibody. All sheep anti-human antibodies were diluted in 
1x TBS/0.2% Tween-20 with 10% nonfat dry milk. Dilutions were recommended by the 
manufacturer (Binding Site). 
Subclass Dilution 
Anti-IgG1 1:4000 
Anti-IgG2 1:4000 
Anti-IgG3 1:2500 
Anti-IgG4 1:3000 
  
 
In addition to HGE, we also performed western blots for constructs of PLA2R 
epitopes. Dr. Dana Sandor and Dr. Hong Ma cultured and transfected human embryonic 
kidney (HEK) 293T cells with vectors containing CysR, CTLD1, and CTLD4-8 (see 
Figure 1 for reference), which we used to asses patient serum reactivity to individual 
PLA2R epitopes. In some cases, the serum dilutions used for western blot was too low to 
detect PLA2R epitopes, and as such we used higher serum concentrations accordingly. 
Experiments pertaining to patient serum samples MN-01 and MN-10 were performed 
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using 1:100 dilution; samples MN-02 and MN-03 using 1:25 dilution; samples MN-04 
through MN-09, MN-11, and MN-13 using 1:50 dilution. 
 
Statistical analysis 
 Where appropriate, data for descriptive statistics were presented as mean ± S.D, 
as there were no outliers present for these summaries. Western blots were assessed semi-
quantitatively and assigned scores ranging from 0 (no response) to 4+ (very strong 
response). For western blot and biopsy immunofluorescence scores, IgG subclass 
predominance was established using the Mann-Whitney U test. We also compared patient 
clinical characteristics and western blot results, and analyzed correlation between these 
using Kendall rank correlation coefficient. Additionally, western blot scores were also 
assigned to one of three distinct strength categories (Table 5). With these values, we 
measured concordance between scores from biopsy immunofluorescence and western 
blot using Cohen’s kappa. For all statistical analysis we used MedCalc v12.5 (MedCalc 
Software) and StataMP 13 (StataCorp). A critical value of P ≤ 0.05 was considered 
significant. 
 
Table 5, Ordinal assignment of western blot and biopsy scores. Western blot scores were 
graded based on intensity of bands, and biopsy scores for immunofluorescence were transcribed 
as provided in the biopsy reports. These numerical scores were then assigned to one of three 
strength categories and used for concordance analysis. 
 
Category Scores 
  Western blot Biopsy 
Negative 0 0, 0.5+ 
Weak 1+, 2+ 1+ to 2.5+ 
Strong 3+, 4+ 3+ to 4+ 
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RESULTS 
 
Anti-PLA2R IgG subclasses in western blot and biopsy 
 All serum samples were from patients with primary MN, confirmed by biopsy 
staining and clinical criteria. The results for western blot (Figure 10) were scored using 
criteria as previously described, and a detailed overview of scores for each sample is 
provided (Tables 6 & 7). We observed 13/13 (100%) samples to have IgG4 
autoantibodies reactive with native PLA2R in HGE. Other subclasses included 11/13 
(84.6%) IgG1, 6/13 (46.2%) IgG2, and 11/13 (84.6%) IgG3. When the band on western 
blot for a subclass was clearly the strongest relative to all others, we deemed that subclass 
to be predominant (Figure 8). If instead two or more of the strongest subclasses had 
similarly intense bands on western blot, we deemed those subclasses to be co-dominant. 
Following this criteria, 10/13 (76.9%) samples were IgG4 predominant, 1/13 (7.7%) 
samples were IgG3 predominant; 2/13 (15.4%) samples were IgG4 co-dominant with 
IgG3. As a whole, a semi-quantitative analysis of western blots showed IgG4 scored 
significantly higher (P ≤ 0.01) than the other subclasses (Figure 9A). 
The same summary and analysis was performed for corresponding biopsy 
immunofluorescence staining data (Tables 8 & 9). All 13/13 (100%) biopsy samples 
stained positive for IgG4, 11/13 (84.6%) for IgG3, 10/13 (76.9%) for IgG2, and 12/13 
(92.3%) for IgG1. IgG4 was the predominant subclass in 11/13 (84.6%) biopsies and co-
dominant with IgG3 in 2/13 biopsies (15.4%). The staining scores indicate strengths of 
IgG subclass immunofluorescence microscopy, which are transcribed directly from the 
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biopsy report, and show predominant IgG4 deposition with moderate contribution from 
the other subclasses (Figure 11). Similar to western blot, IgG4 in biopsy was also scored 
significantly higher (P ≤ 0.01) than were the other subclasses (Figure 9B). 
 
 
Figure 8, Human IgG subclass response against HGE. In western blot, HGE was probed with 
MN-positive serum (1:100 dilution) and recognized bands approximately corresponding to the 
size of PLA2R (~185 kDa), though actual sizes may vary due to extent of N-glycosylation. As 
examples, shown here are: (A) IgG4 predominance; (B) IgG3 predominance; (C) IgG3 and IgG4 
co-dominance. 
 
 
Figure 9, IgG subclass predominance in western blot and biopsy. Mean scores with S.D. for 
A) western blot and B) biopsy immunofluorescence staining. Scoring criteria evaluates strength 
of bands as follows: 0 indicates negative response, 1+ very weak response, 2+ moderate response, 
3+ strong response, 4+ extremely strong response. As the predominant subclass, IgG4 was scored 
significantly higher compared to all other subclasses. Significance is indicated at P ≤ 0.05 (*), P 
≤ 0.01 (**), P ≤ 0.001 (***), or as not significant (ns). 
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Figure 10, Western blot IgG subclass scores. Semi-quantitative results indicating strength of 
reactivity against PLA2R. Scores range from 0 (no response) to 4+ (very strong response). The 
predominant subclass in primary MN is IgG4, as is reflected in the western blot results. 
 
 
Figure 11, Biopsy IgG subclass scores. Strength of immunofluorescence staining for podocyte 
PLA2R. Scores range from 0 (no staining) to 4+ (very strong staining). Though IgG4 is still the 
predominant subclass, other subclasses can be more readily found. In general, anti-PLA2R IgG 
can be more readily detected in glomeruli than in serum.  
23 
Table 6, Scores for IgG subclasses against HGE. Semi-quantitative western blot results for 
patient serum reactivity against PLA2R in HGE. Scores range from 0 (no response) to 4+ (very 
strong response). Predominant subclasses are bolded, co-dominant are underlined. Totals reported 
as n (%). 
Subclass response per sample, western blot 
 IgG1 IgG2 IgG3 IgG4 
MN-01 2+ 0 0 4+ 
MN-02 2+ 0 3+ 1+ 
MN-03 2+ 2+ 3+ 4+ 
MN-04 2+ 0 2+ 3+ 
MN-05 3+ 0 3+ 4+ 
MN-06 1+ 2+ 1+ 4+ 
MN-07 1+ 0 1+ 2+ 
MN-08 2+ 1+ 1+ 4+ 
MN-09 1+ 1+ 1+ 3+ 
MN-10 3+ 2+ 4+ 4+ 
MN-11 2+ 1+ 1+ 3+ 
MN-12 0 0 0 3+ 
MN-13 0 0 2+ 2+ 
Predominant 0 (0) 0 (0) 1 (7.7) 10 (76.9) 
Total positive 11 (84.6) 6 (46.2) 11 (84.6) 13 (100) 
     
 
Table 7, Strength of IgG subclasses against HGE. Summary of western blot scores for patient 
serum reactivity against PLA2R in HGE. Scores are categorized using criteria previously outlined 
in Table 6. Values reported as n (%). 
Subclass response overall, western blot 
  IgG1 IgG2 IgG3 IgG4 
Negative 2 (15.4) 7 (53.8) 2 (15.4) 0 (0) 
Weak 9 (69.2) 6 (46.2) 7 (53.8) 3 (23.1) 
Strong 2 (15.4) 0 (0) 4 (30.8) 10 (76.9) 
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Table 8, Scores for IgG subclass biopsy staining. Immunofluorescence data collected as-is 
from routine biopsy reports. Scores range from 0 (no staining) to 4+ (very strong staining). A 
score of 0.5+ indicates trace amounts of IgG staining, interpreted as negative for statistical 
analysis. Predominant subclasses are bolded, co-dominant are underlined. Scoring criteria 
corresponds to relative strength of each subclass via immunofluorescence. Totals reported as n 
(%). 
Subclass response per sample, biopsy 
 IgG1 IgG2 IgG3 IgG4 
MN-01 2+ 3+ 1+ 4+ 
MN-02 3+ 1+ 3+ 4+ 
MN-03 2.5+ 2.5+ 3+ 4+ 
MN-04 2+ 2+ 4+ 4+ 
MN-05 3+ 2+ 3+ 4+ 
MN-06 2+ 2+ 1+ 4+ 
MN-07 3+ 3+ 3+ 4+ 
MN-08 1+ 0.5+ 0.5+ 2+ 
MN-09 3+ 2+ 2+ 4+ 
MN-10 1+ 0.5+ 3+ 3+ 
MN-11 3+ 1+ 2+ 4+ 
MN-12 2+ 2+ 2+ 4+ 
MN-13 0.5+ 0.5+ 0.5+ 2+ 
Predominant 0 (0) 0 (0) 0 (0) 11 (84.6) 
Total positive 12 (92.3) 10 (76.9) 11 (84.6) 13 (100) 
     
 
Table 9, Strength of IgG subclass biopsy staining. Summary of glomerular staining for IgG 
from routine biopsy reports, with trace amounts of staining being interpreted as negative. Scores 
are categorized using criteria as previously outlined in Table 6. Values reported as n (%). 
Subclass response overall, biopsy 
  IgG1 IgG2 IgG3 IgG4 
Negative 1 (7.7) 3 (23.1) 2 (15.4) 0 (0) 
Weak 7 (53.8) 8 (61.5) 5 (38.5) 2 (15.4) 
Strong 5 (38.5) 2 (15.4) 6 (46.2) 11 (84.6) 
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Correlation between anti-PLA2R IgG and clinical characteristics 
 Using results from western blot measuring serum anti-PLA2R, we examined 
correlation between IgG subclasses and clinical characteristics using the Kendall rank 
correlation coefficient (Table 10). For IgG1, we found significant correlation with 
Caucasian ethnicity (τ = -0.47, P = 0.02); for IgG2 with UPCR (τ = 0.46, P = 0.03); for 
IgG3 with Caucasian ethnicity (τ = -0.42, P = 0.04), serum albumin (τ = -0.51, P = 0.03), 
and negatively with C3 (τ = -0.40, P = 0.04); for IgG4 with serum anti-PLA2R IgG (τ = 
0.48, P = 0.02) and negatively with C1q (τ = -0.53, P = 0.01). 
 
Table 10, Correlation between clinical data and IgG subclasses. We analyzed significant 
correlation between anti-PLA2R IgG subclass responses and patient clinical characteristics. For 
analysis, Caucasian ethnicity = 0, and Asian = 1; for sex, male = 0 and female = 1. Bolded values 
indicates significance at P ≤ 0.05. 
Kendall rank correlation coefficient (τ) 
  IgG1 IgG2 IgG3 IgG4 
Age 0.03 -0.35 0.10 -0.20 
Sex1 -0.12 0.35 0.12 0.12 
Ethnicity2 -0.47 -0.03 -0.42 -0.13 
Clinical information     
    Serum creatinine -0.15 -0.08 -0.27 -0.24 
    Serum albumin 0.04 0.07 0.51 -0.20 
    UPCR 0.21 0.46 0.19 0.09 
    Anti-PLA2R 0.39 0.14 0.21 0.48 
Immunohistological staining     
    C3 -0.07 -0.02 -0.40 0.00 
    C1q -0.05 -0.11 0.15 -0.53 
    Total IgG -0.19 -0.25 0.04 -0.08 
Months after Bx 0.14 0.19 -0.20 0.32 
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Agreement between anti-PLA2R IgG in western blot and biopsy 
 We assessed whether the relative amount of IgG found in immune complex 
deposits, as reflected by the biopsy scores, were concordant or discordant with the 
amount of serum anti-PLA2R IgG as indicated by western blot (Table 11). We used 
Cohen’s kappa to measure concordance, from a score of 0 (total disagreement) up to a 
score of 1 (total agreement). A negative kappa indicates that the observed concordance is 
even less than what would be expected due to random chance. It is also weighted to 
reflect the fact that a score of 2+ versus 3+ is a greater amount of concordance than a 
score of 2+ versus 4+. The scale used for interpreting kappa is typically as follows: < 0, 
less agreement than expected due to chance; 0.01 to 0.20, slight agreement; 0.21 to 0.40, 
fair agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.80, substantial agreement; 
0.81 to 0.99 almost perfect agreement (Viera & Garrett, 2005). Subclasses IgG1 (κ = 
0.264), IgG3 (κ = 0.381), and IgG4 (κ = 0.264) all exhibited fair agreement between 
biopsy immunofluorescence and western blot. IgG2 (κ = -0.140) was the only subclass 
that exhibited more disagreement than was expected due to chance. 
 
Table 11, Concordance rating between western blot and biopsy. We determined the degree of 
concordance between scores obtained from western blot and biopsy staining for each IgG 
subclass. Results exhibiting fair agreement or more (κ ≥ 0.21) are bolded. For statistical analysis 
we used scoring criteria as outlined in Table 6. 
Weighted Cohen's kappa (κ) 
 Kappa Std. error 
IgG1 0.264 0.226 
IgG2 -0.140 0.174 
IgG3 0.381 0.155 
IgG4 0.264 0.313 
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IgG subclasses against PLA2R epitopes in western blot 
 We additionally performed western blot using constructs of three individual 
regions of PLA2R known to contain distinct epitopes CysR, CTLD1, and CTLD4-8 (see 
Figure 1 for reference), which we probed with patient serum samples for reactivity 
against all anti-PLA2R IgG subclasses (Figure 12). In total, we obtained data for reactive 
IgG subclasses using serum samples MN-01 through MN-11 and MN-13 (Table 13). 
MN-07 was the only sample which contained no reactive IgG subclass against any 
PLA2R epitope. For each sample, we have also provided a summary of western blot 
scores, interpreted and assigned as strength of reactivity (Table 12). 
The majority of our samples contained anti-PLA2R IgG directed against epitopes 
within CysR, the most commonly recognized PLA2R domain: 11/12 (91.7%) samples 
contained reactive IgG of any subclass; CTLD1 was positive in 5/12 (41.7%) samples 
tested; CTLD4-8 was positive in 6/12 (50.0%) samples tested. When examining 
individual IgG subclasses, positive reactivity from IgG4 was detected against CysR in 
11/12 (91.7%) cases, and against both CTLD1 and CTLD4-8 in 5/12 (41.7%) cases. IgG1 
reactive against CysR was detected in 8/11 (72.7%) cases, but no IgG1 reactivity was 
detected against the other two domains. IgG3 reactive against CysR was detected in 5/12 
(41.7%) cases; against CTLD1 in 1/11 (8.3%) case; and against CTLD4-8 in 4/12 
(33.3%) cases. No reactivity from IgG2 was detected against any epitope within the three 
PLA2R constructs. In summary, the majority of positive samples contained anti-PLA2R 
reactive against CysR, of which IgG4 was predominant with occasional reactivity from 
IgG1 and IgG3.  
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Table 12, Strength of IgG subclasses against PLA2R epitopes. Summary of western blot scores 
for IgG subclass reactivity against PLA2R epitopes, each categorized by strength based on 
previously stated criteria (Table 5). Strong respondents are bolded. Values reported as n (% of 
instances tested for that dataset). 
Subclass response overall, western blot 
  IgG1 IgG2 IgG3 IgG4 
CysR     
    Negative 3 (27.3) 11 (100) 7 (58.3) 1 (8.3) 
    Weak 3 (27.3) 0 (0) 1 (8.3) 4 (33.3) 
    Strong 5 (45.5) 0 (0) 4 (33.3) 7 (58.3) 
CTLD1     
    Negative 11 (100) 11 (100) 11 (91.7) 7 (58.3) 
    Weak 0 (0) 0 (0) 1 (8.3) 3 (25.0) 
    Strong 0 (0) 0 (0) 0 (0) 2 (16.7) 
CTLD4-8     
    Negative 11 (100) 11 (100) 8 (66.7) 7 (58.3) 
    Weak 0 (0) 0 (0) 4 (33.3) 3 (25.0) 
    Strong 0 (0) 0 (0) 0 (0) 2 (16.7) 
     
 
 
Figure 12, IgG4 against PLA2R epitopes in sample MN-01. Circulating IgG4 (1:100 dilution) 
reactive against PLA2R epitopes. Red arrows indicate approximate location of epitopes: ~20 kDa 
for both CysR and CTLD1, ~90 kDa for CTLD4-8. Expected protein sizes were determined using 
ProtPram (Swiss Institute of Bioinformatics) by the lab of Dr. Laurence Beck, though actual sizes 
in assay may vary due to extent of N-glycosylation.  
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Table 13, Scores for IgG subclasses against PLA2R epitopes. Semi-quantitative western blot 
results for patient serum reactivity against PLA2R epitopes. Scores range from 0 (no response) to 
4+ (very strong response). Predominant subclasses are bolded, co-dominant are underlined. For 
comparison purposes, western blot scores against PLA2R in HGE are included as well, as are 
ELISA titers (RU/mL) for anti-PLA2R total IgG. No PLA2R epitope data was collected from 
sample MN-12. Totals reported as n (%). 
Subclass response per sample, western blot 
 IgG1 IgG2 IgG3 IgG4 ELISA 
MN-01, HGE 2+ 0 0 4+ 188.5 
    CysR 4+ 0 0 4+  
    CTLD1 0 0 0 3+  
    CTLD4-8 0 0 0 4+  
MN-02, HGE 2+ 0 3+ 1+ 18.52 
    CysR 3+ 0 4+ 1+  
    CTLD1 0 0 0 0  
    CTLD4-8 0 0 1+ 0  
MN-03, HGE 2+ 2+ 3+ 4+ 85.63 
    CysR 2+ 0 0 4+  
    CTLD1 0 0 0 2+  
    CTLD4-8 0 0 0 0  
MN-04, HGE 2+ 0 2+ 3+ 326.3 
    CysR 2+ 0 2+ 4+  
    CTLD1 0 0 0 0  
    CTLD4-8 0 0 0 0  
MN-05, HGE 3+ 0 3+ 4+ 493.4 
    CysR 2+ 0 4+ 4+  
    CTLD1 0 0 0 1+  
    CTLD4-8 0 0 0 1+  
MN-06, HGE 1+ 2+ 1+ 4+ 148.4 
    CysR 0 0 0 2+  
    CTLD1 0 0 0 1+  
    CTLD4-8 0 0 1+ 1+  
MN-07, HGE 1+ 0 1+ 2+ 24.89 
    CysR 0 0 0 0  
    CTLD1 0 0 0 0  
    CTLD4-8 0 0 0 0  
MN-08, HGE 2+ 1+ 1+ 4+ 13.67 
    CysR 0 0 0 3+  
    CTLD1 0 0 0 0  
    CTLD4-8 0 0 0 0  
MN-09, HGE 1+ 1+ 1+ 3+ 146.2 
    CysR 3+ 0 0 1+  
    CTLD1 0 0 0 0  
    CTLD4-8 0 0 0 0  
(Continued)      
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Subclass response per sample, western blot (continued) 
 IgG1 IgG2 IgG3 IgG4 ELISA 
MN-10, HGE 3+ 2+ 4+ 4+ 355.4 
    CysR 3+ 0 3+ 4+  
    CTLD1 0 0 2+ 4+  
    CTLD4-8 0 0 1+ 4+  
MN-11, HGE 2+ 1+ 1+ 3+ 62.96 
    CysR 3+ 0 0 2+  
    CTLD1 0 0 0 0  
    CTLD4-8 0 0 0 0  
MN-13, HGE 0 0 2+ 2+ 58.87 
    CysR n/a n/a 3+ 3+  
    CTLD1 n/a n/a 0 0  
    CTLD4-8 n/a n/a 2+ 1+  
Total CysR 8/11 (72.7) 0/11 (0) 5/12 (41.7) 11/12 (91.7)  
Total CTLD1 0/11 (0) 0/11 (0) 1/12 (8.3) 5/12 (41.7)  
Total CTLD4-8 0/11 (0) 0/11 (0) 4/12 (33.3) 5/12 (41.7)  
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Agreement between IgG against full-length PLA2R and epitopes 
We used western blot to assess the reactivity of IgG subclasses in serum against 
full-length PLA2R found in HGE, and compared it to reactivity against the three PLA2R 
epitopes (Table 14). We used Cohen’s kappa to measure concordance between western 
blot scores in the same methods and scoring criteria as outlined previously (Viera & 
Garrett, 2005). Overall, the strongest agreement between autoantibodies directed against 
full-length PLA2R and individual epitopes was observed against CysR: IgG1 (κ = 0.022) 
exhibited slight agreement between the two targets, whereas IgG3 (κ = 0.342) and IgG4 
(κ = 0.231) exhibited fair agreement. Autoantibodies against epitopes CTLD1 and 
CTLD4-8 exhibited slight agreement (from κ = 0.057 to 0.127) for reactivity with 
subclasses IgG3 and IgG4; IgG1 did not react with either of these epitopes. We found 
IgG2 to be completely unreactive with all PLA2R epitopes, and thus exhibited no 
concordance with reactivity to the full-length molecule. 
We also compared the reactivity of circulating IgG subclasses against PLA2R 
epitopes with biopsy immunofluorescence data for corresponding IgG subclasses. 
Curiously, biopsy results exhibited considerably more agreement with western blot 
results for full-length PLA2R, than with any of the epitopes. While several epitopes 
exhibited fair agreement with biopsy (CysR for IgG1; CysR, CTLD1 for IgG3; CTLD1, 
CTLD4-8 for IgG4), most notably anti-CysR IgG4 exhibited more disagreement with 
biopsy immunofluorescence for IgG4 than expected due to chance (κ = -0.263), 
especially surprising as anti-CysR IgG4 exhibited fair agreement with reactivity against 
full-length PLA2R.  
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Table 14, Concordance rating between PLA2R, epitopes, and biopsy. We determined the 
degree of concordance between IgG subclass reactivity to PLA2R epitopes, full-length PLA2R in 
HGE, and biopsy immunofluorescence. Results exhibiting fair agreement or more (κ ≥ 0.21) are 
bolded. For statistical analysis we used scoring criteria as outlined in Table 6. 
Subclass Full-length PLA2R Biopsy 
 Kappa Std. error  Kappa Std. error 
IgG1      
    CysR 0.022 0.156  0.172 0.191 
    CTLD1 0.000 0.000  0.000 0.000 
    CTLD4-8 0.000 0.000  0.000 0.000 
IgG2      
    CysR 0.000 0.000  0.000 0.000 
    CTLD1 0.000 0.000  0.000 0.000 
    CTLD4-8 0.000 0.000  0.000 0.000 
IgG3      
    CysR 0.342 0.151  0.122 0.186 
    CTLD1 0.127 0.113  0.020 0.024 
    CTLD4-8 0.057 0.059  -0.047 0.094 
IgG4      
    CysR 0.231 0.214  -0.263 0.157 
    CTLD1 0.067 0.053  0.043 0.039 
    CTLD4-8 0.067 0.055  0.043 0.040 
      
 
Correlation between anti-CysR IgG and clinical characteristics 
 We analyzed correlation between IgG subclass responses against CysR and 
patient clinical characteristics, particularly because response against CysR exhibited the 
greatest concordance with IgG subclass responses as a whole. Using Kendall rank 
correlation coefficient, we found significant correlation between anti-CysR IgG 
subclasses and the following (Table 15): for IgG1 with age (τ = 0.52, P = 0.03); for IgG3 
negatively with serum creatinine (τ = -0.43, P = 0.04) and negatively with C3 (τ = -0.41, 
P = 0.05); for IgG4 with serum anti-PLA2R (τ = 0.52, P = 0.03). Correlation between 
IgG3 with C3 staining, and IgG4 with levels of serum anti-PLA2R IgG were also 
observed. 
33 
Table 15, Correlation between clinical data and CysR reactivity. We analyzed significant correlation between anti-CysR IgG subclass 
responses and patient clinical characteristics. We were unable to calculate a correlation coefficient for IgG2 as it exhibited no reactivity 
with CysR. For analysis, Caucasian ethnicity = 0, and Asian = 1; for sex, male = 0 and female = 1. Bolded values indicates significance at 
P ≤ 0.05. 
Kendall rank correlation coefficient (τ) 
  IgG1 IgG2 IgG3 IgG4 
Age 0.52 P = 0.03 n/a  0.40  0.34  
Sex1 -0.22  n/a  0.00  0.05  
Ethnicity2 0.23  n/a  -0.26  -0.34  
Clinical information         
    Serum creatinine 0.31  n/a  -0.43 P = 0.04 -0.19  
    Serum albumin -0.18  n/a  0.32  -0.08  
    UPCR 0.27  n/a  -0.17  -0.29  
    Anti-PLA2R 0.19  n/a  0.24  0.49 P = 0.03 
Immunohistological staining         
    C3 0.05  n/a  -0.41 P = 0.05 -0.19  
    C1q -0.24  n/a  -0.13  -0.40  
    Total IgG -0.06  n/a  0.00  -0.07  
Months after Bx -0.08  n/a  -0.15  -0.03  
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DISCUSSION 
 
Use of autoantibodies to PLA2R as a diagnostic and prognostic biomarker has 
increased considerably since its discovery in 2009. Research groups have shown IgG4 
predominance in circulation (Hofstra, et al., 2012) and in glomerular deposits (Doi, 
Mayumi, Kanatsu, Suehiro, & Hamashima, 1984), though so far studies have lacked a 
comprehensive comparison of all IgG subclasses in both locations. In the present we have 
reinforced that knowledge by specifically showing concordance between levels of anti-
PLA2R IgG subclasses in serum and IgG subclass levels within glomerular deposits as 
indicated by renal biopsy. We have also demonstrated concordance between levels of 
particular circulating IgG subclasses against full-length PLA2R as against the CysR, 
CTLD1, and CTLD4-8 domains, each of which harbors a unique epitope. 
A potential concern about our results is that immunofluorescence for IgG 
subclasses, as indicated by the routine biopsy reports, might represent multiple IgG 
specificities, some of which may be directed against antigens other than PLA2R. While 
this may appear to limit our conclusions comparing circulating and deposited IgG, there 
is in fact evidence that IgG in glomerular deposits is predominantly and specifically anti-
PLA2R. Acid elution from biopsy tissue has demonstrated that anti-PLA2R IgG4 can be 
specifically eluted from biopsies of primary MN patients, but not from those of secondary 
MN patients or other disease controls (Beck, et al., 2009). Several studies have shown 
precise co-localization of the PLA2R antigen and IgG4. However, neither of these 
observations preclude the existence of antibodies directed against other glomerular 
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antigens. A rare case involving a monoclonal IgG3κ anti-PLA2R associated with 
recurrent MN is instructive, in that subepithelial deposits in both the kidney allograft and 
the native kidney contained only IgG3κ (Debiec, et al., 2012). Had there been 
immunoglobulins directed against antigens other than PLA2R, it is extremely unlikely 
that they would have also been restricted to this subclass and particular light chain. Using 
conclusions drawn from these two studies, we consider the biopsy staining results for IgG 
subclasses to be a good approximation of IgG specific against PLA2R, and thus in our 
study we have assessed biopsy results under this assumption. 
 
Anti-PLA2R directed against HGE 
As measured by western blot, anti-PLA2R levels within the patient serum samples 
conformed to subclass distributions typically exhibited in serum of primary MN patients. 
Our observation of circulating IgG4 predominance, and a weaker presence of circulating 
IgG1 and IgG3, is also consistent with previous conclusions that glomerular deposits in 
primary MN contain chiefly IgG4, potentially with weaker IgG1 and IgG3 staining 
depending on the stage of disease (Huang, et al., 2013). Generally, IgG subclass 
distribution measured by western blot, excluding IgG2, was concordant with subclass 
staining in biopsy reports. IgG2 presented as the weakest subclass when measured by 
both, but was more strongly detected in glomerular deposits: there was a 46.2% positive 
detection rate in western blot and 76.9% positive detection rate in biopsy (Tables 6 & 8), 
which represented the lowest rate for each group. Biopsy immunofluorescence usually 
scored higher for all samples compared to western blot (Figures 10 & 11) This 
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discrepancy is not surprising since podocyte PLA2R “can be detected in antibody-
negative patients,” owing to the higher sensitivity for detecting PLA2R antigen compared 
to its corresponding autoantibody (Ronco & Debiec, 2014), in addition to detecting 
deposited IgG in patients who have entered immunological remission (Beck, et al., 2009). 
Because the biopsy reflects IgG deposits accumulated over a period of several months to 
years, it is expected to score higher than a serum sample which only represents a single—
and thus immunologically weaker—time point, especially when a patient goes into 
remission. We alleviated this inherent disagreement by grouping western blot and biopsy 
scores into strength categories (Table 5) and then performed concordance analysis. Based 
on these results, we conclude that for most (but not all) patients with primary MN, 
circulating IgG were fairly reflective of IgG deposited in glomeruli over the entire time 
course of a patient’s disease. 
Notably, there were three cases measured by western blot in which circulating 
IgG4 was not the predominant subclass: IgG3 was dominant in one case (MN-02), and 
co-dominant with IgG4 in two cases (MN-10 and MN-13). The predominance of 
circulating IgG3 was unexpected, as its corresponding biopsy exhibited IgG4 
predominance. There is significant positive correlation between circulating IgG4 and 
anti-PLA2R total IgG, and MN-02 was also reported to have the lowest anti-PLA2R titer 
among all patient samples, offering a serological explanation for the weak reactivity of 
IgG4 by western blot. Additionally, the western blot is performed using a serum sample 
representing a single time point during the patient’s immunological course of disease, 
whereas biopsy immunofluorescence is the result of accumulated immune complex 
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deposition over a much longer period of time. Another hypothetical explanation for the 
lack of IgG4 predominance may be due to an unrecognized secondary cause of MN or 
coincidental condition, one which may not have been clearly indicated in the patient’s 
biopsy report. In such cases, inflammatory diseases or malignancies produce an immune 
response which may divert antibody production away from the IgG4 subclass. Cell-
mediated immunity conferred by activation of Type 1 T-helper cell (Th1) populations is 
directed against bacterial and viral infections (Kuby, 1997), and also against tumor cells 
(Hung, et al., 1998). In contrast, humoral responses driven by predominately by the Th2 
population leads to increased immunoglobulin production, especially of the IgG4 
subclass, and is more associated with primary MN (Hirayama, et al., 2002). Activation of 
one T-helper cell subset can inhibit the other (Kuby, 1997), which provides a possible 
explanation for circulating IgG3 predominance and not IgG4, though the evidence is 
mostly circumstantial for this particular case. Supporting these ideas, we also performed 
western blot against HGE using four patient serum samples featuring malignancy-
induced secondary MN. In three samples we detected prominent circulating IgG1, IgG3, 
in addition to strong IgG4, and in the fourth sample, predominantly IgG4 and a lesser 
amount of IgG3 (data not shown). More data should be obtained from MN patients with 
malignancy-associated cases to derive more insight regarding the distribution of 
circulating IgG subclasses. 
So far, our findings provide more insight regarding IgG subclass distribution, 
though conclusive data for their pathological roles in primary MN is still lacking. 
Previous studies have shown that IgG1 and IgG3 are able to activate the classical 
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complement cascade, and positively correlate with C1q staining (whereas IgG4 correlates 
negatively with classical complement component C1q) which implies that these 
subclasses may cause damage via complement in earlier stages of primary MN 
progression (Huang, et al., 2013). This idea is further grounded in fetomaternal 
alloimmune MN, wherein cases exhibit both IgG1 and IgG4 anti-NEP predominance, and 
complement-fixing IgG are additionally required to cause proteinuria (Vivarelli, et al., 
2015). We found statistically significant negative correlation between circulating IgG4 
and glomerular C1q staining (Table 10), a relationship that Huang et al. also established 
with glomerular IgG4. As IgG4 is unable to activate complement by the classical 
pathway, there may be a physiological foundation for these results. In our study, 
however, we were unable to establish significant correlation between either IgG1 or IgG3 
and C1q. Therefore, it is difficult to make further assertions concerning the role of 
complement activation in primary MN based solely on our results. 
 
Anti-PLA2R directed against epitopes 
A majority of autoantibodies were reactive against CysR (91.7% total samples 
were positive for anti-CysR IgG of any subclass), and the rest exhibited minor reactivity 
against CTLD1 and CTLD4-8 (Table 13). This is consistent with previous findings in 
which the immunodominant epitope was contained within the CysR region (Fresquet, et 
al., 2015). However, in a different study reactivity with anti-PLA2R was only established 
with an epitope construct encompassing CysR-FNII-CTLD1; reactivity was completely 
abolished when CTLD1 was removed from the construct, possibly due to the latter 
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epitope influencing conformation via disulfide bonding (Kao, Lam, Waldman, Glassock, 
& Zhu, 2015). We were able to detect reactivity to the isolated CysR epitope, and this 
may be due to the fact that in our experiments serum was typically diluted between 1:25 
and 1:100, compared to the 1:1000 dilution used for most experiments in Kao et al. 
(1:100 was our default dilution for all experiments, decreasing down to 1:25 in some 
cases that were undetectable at the former dilution). While some of our serum samples 
were also reactive with PLA2R epitopes at higher dilutions, most required at least 1:100 
dilution or lower for detection by western blot (data not shown). 
In most cases, we have also shown circulating autoantibodies reactive with 
individual epitopes to be IgG4 predominant and most widespread: IgG4 reactive against 
CysR was found in almost all serum samples, and reactive against CTLD1 and CTLD4-8 
in approximately half of all samples (Table 13). Additionally, serum anti-CysR IgG3 and 
IgG4 (the two most reactive subclasses overall against PLA2R epitopes) exhibited fair 
agreement with levels of IgG3 and IgG4 reactive against full-length PLA2R, indicating 
that for these two subclasses, the immunogenicity of CysR as well as anti-CysR subclass 
distribution mirrors that of the full-length molecule (Table 14). In contrast, reactivity 
against CTLD1 and CTLD4-8 for both IgG3 and IgG4 exhibited only slight agreement 
with reactivity against full-length PLA2R; these epitopes may not be as effective an 
indicator of primary MN if they were used in isolation. Nevertheless, with the exception 
of a single case (MN-06) autoantibodies reactive against CTLD1 and CTLD4-8 were 
never detected unless anti-CysR IgG was also present, and even in the single anomalous 
case anti-CTLD4-8 IgG was only weakly positive. Interestingly, anti-CysR IgG4 was not 
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the predominant subclass in four cases: IgG4 exhibited co-dominance with anti-CysR 
IgG1 in one case (MN-01), was subdominant to IgG1 in two more cases (MN-09 and 
MN-11), and subdominant to IgG3 in another (MN-02). IgG1 predominance in MN-09 
and MN-11 was unexpected, as this was not reflected at all in western blot for full-length 
PLA2R—in fact, in these experiments IgG1 reactivity was rated “very weak” and 
“moderate,” respectively. At present, we cannot offer a satisfactory explanation for this 
discrepancy. On the other hand, the unusual IgG3 predominance in MN-02 was more 
expected as this was also observed in the same sample against full-length PLA2R, 
reinforcing the idea of CysR primacy. 
To conclude, predominance of IgG4 reactivity towards PLA2R domains 
containing epitopes CysR, CTLD1, and CTLD4-8 carries over from the full-length 
molecule, and overall CysR epitope garners the strongest immune responses. We observe 
both IgG3 and IgG4 to exhibit concordance when reactive against CysR and the full-
length PLA2R, and we also observe circulating autoantibody reactivity against CTLD1 
and CTLD4-8 to usually occur when there is also stronger anti-CysR reactivity. CysR has 
potential as an adequate marker primary MN, especially when used to observe IgG4 
predominance. Based on the lack of universal reactivity to CysR demonstrated by our 
data, we still urge caution against using anti-CysR IgG4 exclusively to monitor 
immunologic disease activity of primary MN in general. Applied use of anti-CysR as a 
biomarker to monitor treatment of primary MN should complement, and not replace, 
existing standards. 
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Limitations, future directions, and final remarks 
As with most statistical analyses, we need to address the possibility of type I and 
type II errors in our correlations between IgG subclasses measured in western blot and 
clinical characteristics. With some clinical features, we occasionally detected significant 
correlations (based on P ≤ 0.05 for significance) that were either unexpected, 
unconvincing, or with poor theoretical plausibility. IgG1 and IgG3 were correlated with 
Caucasian ethnicity, and IgG3 negatively with C3 staining (Table 10). For ethnicity, 
though MN tends to affect the Caucasian population more strongly (Salant & Cattran, 
2010), 10/13 of our patient samples were also Caucasian, the limited number of subjects 
from other ethnic groups weakens our result. The negative correlation between 
circulating IgG3 and C3 staining was another curious case, as one would expect high 
levels of complement-activating IgG3 to also be associated with high levels of 
complement components, as has been established in previous studies (Huang, et al., 
2013). We also explored options to reduce possible false positive errors using Bonferroni 
correction, which rendered all of our results non-significant due to increased stringency 
for the P-value requirement. This method also increases false negative rates, and its usage 
is cautioned unless a large number of multiple comparisons testing a single universal null 
hypothesis are involved (Armstrong, 2014). Instead, a more effective and necessary 
method may be to simply use larger sample groups, which could also improve the quality 
of all statistical findings. It is worth mentioning, however, that larger sample groups may 
exacerbate the problem of biopsy scores being obtained from different pathologists. This 
would produce an additional source of heterogeneity which may have affected our results 
42 
in this study. A final concern regards our use of semi-quantitative scoring on a scale of 0 
through 4+ for western blot, which may limit our choices in statistical analysis and their 
robustness. Ideally, more quantitative results for western blot can be obtained by 
performing densitometry analysis to produce continuous values. However, this technique 
is more sensitive to variation—our western blots were performed over a period of time 
without a reliable internal control, and as such we are not able to use this technique for a 
post-hoc analysis. 
Evaluating immunogenicity of specific PLA2R epitopes involves some additional 
challenges. In our experiment, we did not test for reactivity against CTLD2 or CTLD3 
due to limited reactivity observed in previous experiments (data not shown), nor against 
any individual epitopes within CTLD4-8 due to technical issues expressing these 
domains in isolation. As conformational epitopes of PLA2R are known to exist, one can 
speculate that testing IgG subclass reactive against different sequential combinations may 
reveal epitopes previously hidden, though this may also introduce new and non-
physiological epitopes that would have been undetected natively. Related to this issue, we 
had attempted blotting HGE directly onto nitrocellulose membrane, without intervention 
from the denaturing step (heating in an excess of SDS) associated with SDS-PAGE. We 
had hoped to find whether anti-PLA2R IgG directed against HGE would differ depending 
on presence of denaturing conditions, but were unable to observe any differences in 
preliminary experiments (data not shown). 
Detecting serum anti-PLA2R autoantibody levels has proven to be a valuable tool 
in evaluating disease and guiding patient treatment. With increased prominence and 
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availability of commercial immunofluorescence kits and ELISA assays, we are now able 
to quickly and accurately measure levels of circulating anti-PLA2R, and possibly 
reducing the need for intrusive biopsies. Regardless, when testing patients for circulating 
anti-PLA2R, we are still unable to detect autoantibodies in approximately 20% to 30% of 
cases. This may be due to differences between assays, patients achieving immunological 
remission, or primary MN caused by a different antigen entirely. Partly due to these 
reasons, some researchers urge caution before elevating anti-PLA2R titers to the status of 
a diagnostic end-all (Hofstra & Wetzels, 2012). In particular, the cohort of primary MN 
patients with missing reactivity to PLA2R have prompted researchers to speculate about 
as-of-yet unknown glomerular antigens and their involvement in primary MN. Very 
recently thrombospondin type-1 domain-containing 7A (THSD7A), a transmembrane 
podocyte protein similar to PLA2R, was identified by our laboratory, in collaboration 
with two European groups, to be another antigenic target that can cause immune complex 
deposition and primary MN (Tomas, et al., 2014). In this study, less than 10% of patients 
with primary MN but without reactivity to PLA2R contained anti-THSD7A 
autoantibodies, leaving the possibility of yet more undiscovered antigenic targets in 
primary MN. 
The time delay experienced between immunological and clinical markers of the 
disease posed a challenge to the analysis and interpretation of our data. Since our samples 
were collected as individual time-points in relation to their biopsies, we did not have 
thorough descriptions of the patients’ disease progression—the overall lack of correlation 
between patient clinical characteristics and serum anti-PLA2R IgG subclass levels may be 
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attributed to this fact, as may the occasional discrepancy between reactivity against full-
length PLA2R and its epitopes. Whether such disagreement between clinical conditions 
and anti-PLA2R levels were truly due to lack of correlation, or due to mismatched phases 
of immunological or clinical disease is difficult to conclusively determine without 
additional data and more thorough clinical history. The high affinity of anti-PLA2R 
autoantibodies for podocyte PLA2R can explain some of these effects for patients with 
early stages of primary MN. The absorption of circulating IgG from plasma at a faster 
rate than that by which it can be produced may lead to a circumstance in which there is 
no detectable circulating anti-PLA2R while IgG- and antigen-containing deposits already 
exist within the biopsy. Once the immunological disease and antibody production 
increases, anti-PLA2R may then be more easily detected in circulation: 
“This could explain the clinical paradox of PLA2R-positive biopsy specimens 
associated with absence of anti-PLA2R antibodies in the serum…These biopsy-
positive, seronegative cases may, therefore, represent an early phase of…primary 
disease and in recurrent disease” (Fresquet, et al., 2015). 
 
Alternatively, patients who have resolving immunologic disease but have not undergone 
clinical remission also exhibit proteinuria in absence of circulating anti-PLA2R, and lead 
to discrepancies between autoantibody titers and clinical characteristics. This explanation 
had been previously evidenced in cases of primary MN patients with undetectable serum 
titers of anti-PLA2R but positive glomerular staining for the same, suggesting that 
symptoms may persist after autoantibody clearance from circulation due to long-term 
ultrastructural damage which had yet to be repaired (Debiec & Ronco, 2011). In light of 
this information, some of the discrepancies observed between IgG subclasses directed 
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against full-length PLA2R, its epitopes, and immunofluorescence may be attributed to the 
progressing stages of filtration barrier damage and repair, as well as to rapid clearance 
and deposition of circulating autoantibodies. 
Despite these challenges, anti-PLA2R has so far proven useful as a clinical guide 
for diagnosis and treatment of primary MN. We have now added to this body of 
knowledge by demonstrating an overall consistency of distribution for all subclasses 
between serum and tissue. We have also shown IgG4 predominance in reactivity to 
individual PLA2R epitopes, and despite previously described limitations these 
observations can serve to enhance the understanding of primary MN. By undertaking 
additional studies in the future incorporating more detailed patient history, clinical 
characteristics, as well as a larger cohort size, researchers and physicians in this field may 
hopefully codify more concise relationships between these biomarkers and apply this 
knowledge towards better treatment and care of patients with primary MN.  
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APPENDIX 
 
Results for western blot of all patient samples. 
 
Figure 13, All IgG subclass responses against HGE. Western blot exposures of patient serum 
samples (indicated by sample number and corresponding biopsy report identifiers). HGE was 
probed with MN-positive serum (1:100 dilution), and recognized bands approximately 
corresponding to the size of PLA2R (~185 kDa). The blots pictured here were exposed for 30s 
each.  
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(Continued from previous section.) 
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Results for western blot of all samples, grouped by PLA2R epitope. 
 
 
Figure 14, All IgG subclass responses against PLA2R epitopes. Western blot exposures of 
patient serum samples (indicated by sample number and corresponding biopsy report identifiers). 
Domains of PLA2R containing three epitopes constructs were probed with MN-positive serum 
(dilutions ranging from 1:25 to 1:100), and recognized bands approximately corresponding to the 
sizes of CysR (~20 kDa), CTLD1 (~20 kDa), and CTLD4-8 (~90 kDa). The blots pictured here 
were exposed for 30s each. 
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(Continued from previous section.) 
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(Continued from previous section.) 
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(Continued from previous section.) 
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(Continued from previous section.) 
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(Continued from previous section. Western blot was not performed with IgG1 and IgG2 
for sample MN-13) 
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Table 16, Clinical characteristics of patient samples. Clinical information for each patient as indicated in the biopsy reports. 1Serum 
creatinine (mg/dL). 2Serum albumin (g/dL). 3Serum anti-PLA2R as measured by ELISA (RU/mL). 4Months elapsed after biopsy date that 
serum sample was taken (serum for MN-13 was taken before the corresponding biopsy). 
Sample Age Sex Ethnicity S. cr.1 S. albu.2 UPCR Anti-PLA2R3 C3 C1q Total IgG Mos.4 
MN-01 70 M Caucasian 1.95 1.7 8 188.5 3+ 0+ 4+ 5.6 
MN-02 71 M Caucasian 1.25 4 9.5 18.52 2+ 1+ 4+ 2.1 
MN-03 63 M Caucasian 1.7 3.2 11.1 85.63 2+ 1+ 4+ 0.7 
MN-04 79 F Caucasian 1.4 n/a 3.13 326.3 2+ 0.5+ 4+ 1 
MN-05 57 M Caucasian 1.02 2.2 8.2 493.4 2+ 0+ 4+ 3 
MN-06 34 F Caucasian 0.75 2.2 8.4 148.4 3+ 0+ 4+ 13 
MN-07 34 M Caucasian 3.02 2.4 9.87 24.89 3+ 2+ 4+ 11.1 
MN-08 53 F n/a 0.7 3.7 5.3 13.67 0.5+ n/a 3+ 4.7 
MN-09 59 F Asian 2.02 2.3 19.7 146.2 2+ 0+ 4+ 1.5 
MN-10 64 F Caucasian 1.3 3.5 19 355.4 1+ 0+ 3+ 19 
MN-11 54 M Caucasian 2.7 1.7 16 62.96 3+ 1+ 3+ 3 
MN-12 77 M Asian 2.3 n/a 5.2 33.12 2+ 0+ 3.5+ 4 
MN-13 69 F Caucasian 0.66 2.8 3.74 58.87 0+ n/a 3.5+ -0.6 
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